Waters Corp (WAT)
Health Services • Health Care
Financial Metrics
Price to Earnings246.1x
Revenue Growth (1Y)52.47%
Debt to Equity0.34x
Strengths
Valuation
Waters Corp is overvalued
News
All
Press Releases
News
Filings

August 11, 202610-Q Quarterly Report for 2026 Q2

August 04, 2026 Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

July 27, 2026 Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer

July 02, 2026 Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call

June 24, 2026 IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

June 09, 2026 Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis

June 08, 2026 Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

June 03, 2026 Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics

June 01, 2026 Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics

June 01, 2026 Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research

May 18, 2026 Waters Corporation to Present at the Jefferies Global Healthcare Conference

May 12, 202610-Q Quarterly Report for 2026 Q1

May 05, 2026Waters CEO highlights China as key innovation source in the biopharma market

May 05, 2026 Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results

April 20, 2026 Waters Corporation Schedules First Quarter 2026 Earnings Conference Call

April 15, 2026 Waters Announces CE Mark for Next-Generation Fully Automated BD BACTEC FXI Culture System for Bloodstream Infection Diagnosis

April 14, 2026 Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules

April 08, 2026Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit

April 08, 2026 Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay

March 18, 2026 Waters Prices Offering of Senior Notes

March 09, 2026 Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed

February 23, 2026 Waters Corporation to Present at the TD Cowen Health Care Conference

February 23, 202610-K Annual Report for 2025 FY

February 17, 2026 Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage

February 10, 2026What's Going On With Becton Dickinson Stock Tuesday?

February 09, 2026Software Stocks Rebound, Silver Rallies 6% To $82: What's Moving Markets Monday?

February 09, 2026Why Is Waters Stock Sinking Monday?

February 09, 2026Becton Dickinson Slashes Profit Outlook Post-Spinoff

February 09, 2026 Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

February 09, 2026 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

January 27, 2026 Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

January 20, 2026 Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call

January 06, 2026Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst

December 23, 2025 Waters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026

November 11, 2025 Waters Corporation to Present at the Jefferies Global Healthcare Conference in London

November 11, 2025 Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software

November 06, 2025Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal

November 04, 2025 Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

November 04, 202510-Q Quarterly Report for 2025 Q3

October 13, 2025 Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

October 01, 2025 Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call

August 26, 2025 Waters Corporation to Present at the Wells Fargo Healthcare Conference

August 04, 202510-Q Quarterly Report for 2025 Q2

July 20, 2025Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?

July 14, 2025Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger

May 06, 2025Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?

May 06, 202510-Q Quarterly Report for 2025 Q1

March 26, 2025This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

February 25, 202510-K Annual Report for 2024 FY

November 01, 202410-Q Quarterly Report for 2024 Q3

July 31, 202410-Q Quarterly Report for 2024 Q2

May 07, 202410-Q Quarterly Report for 2024 Q1

February 27, 202410-K Annual Report for 2023 FY

November 07, 202310-Q Quarterly Report for 2023 Q3

August 02, 202310-Q Quarterly Report for 2023 Q2

May 09, 202310-Q Quarterly Report for 2023 Q1

February 27, 202310-K Annual Report for 2022 FY

November 03, 202210-Q Quarterly Report for 2022 Q3

August 04, 202210-Q Quarterly Report for 2022 Q2

May 05, 202210-Q Quarterly Report for 2022 Q1

February 24, 202210-K Annual Report for 2021 FY

November 04, 202110-Q Quarterly Report for 2021 Q3
A. Company Overview
Waters Corporation stands as a global leader in analytical instruments and software, specializing in chromatographic and mass spectrometric technologies, thermal analysis, rheometry, and calorimetry for over 65 years. Headquartered in Milford, Massachusetts, the company has established its presence with approximately 7,900 employees operating in over 35 countries, while its products are available in more than 100 countries globally. Waters Corporation designs, manufactures, sells, and services high-performance analytical systems, including high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), mass spectrometry (MS) technology, and thermal analysis equipment through its TA Instruments brand. These analytical technologies are integral in various fields such as pharmaceutical, clinical, biochemical, industrial, nutritional safety, environmental analysis, academic research, and government applications.
Waters Corporation has evolved through significant technological advancements and strategic acquisitions, enhancing its portfolio over time. Key acquisitions include TA Instruments in 1996, Micromass Limited in 1997, and Wyatt Technology in 2023. The acquisition of Wyatt Technology, known for its pioneering work in innovative light scattering techniques and fractionation instruments, aims to bolster Waters’ capabilities in the large molecule market.
B. Business Segments
Waters Corporation's operations can be categorized primarily into two significant segments: Waters and TA (TA Instruments).
Waters Segment
The Waters segment focuses on the design, manufacture, and sale of HPLC and MS systems along with associated consumable products such as chromatography columns and other precision chemistry consumables. With its stronghold in the pharmaceutical and life sciences markets, this segment addresses critical applications including drug discovery, clinical trial testing, and environmental testing.
TA Segment
The TA segment specializes in developing thermal analysis, rheometry, and calorimetry instruments, essential for evaluating the thermal properties of various materials in industries ranging from pharmaceuticals to electronics.
Both segments are integrated into a singular reporting category for financial purposes due to their similar economic characteristics and customer demographics.
C. Products and Markets
Waters Corporation's extensive range of products is designed to meet the diverse needs of analytical workflows across various industries.
High-Performance and Ultra-Performance Liquid Chromatography
HPLC serves as a fundamental analytical technique essential for identifying and analyzing chemical components across different materials. It is particularly significant in pharmaceutical research, quality control, and compliance testing. The introduction of ultra-performance liquid chromatography (UPLC) has brought advancements in speed and resolution of chemical separations, notably with systems like the ACQUITY UPLC, which allows for higher sensitivity in analysis and compatibility with existing workflows.
Key applications include:
- Pharmaceutical Development: HPLC is crucial for drug characterization, potency verification, and manufacturing processes.
- Environmental Testing: HPLC is employed in monitoring air and water purity.
- Quality Assurance: Nutritional testing in food and beverages, along with compliance verification for safety standards.
Recent innovations in LC products, such as the ACQUITY Premier LC solution and the newly introduced DynaPro ZetaStar for nanoparticle analysis, showcase the company’s commitment to enhancing performance and functionality.
Mass Spectrometry and Liquid Chromatography-Mass Spectrometry
Waters Corporation is recognized for its robust portfolio of MS instruments, which are vital for compound identification, quantification, and structural elucidation. The MS systems are often integrated with LC systems, enhancing their analytical capabilities through advanced technologies like time-of-flight (ToF) and ion mobility spectrometry.
Noteworthy applications are found within:
- Proteomics: Understanding disease mechanisms via protein analysis.
- Clinical Testing: High-resolution detection for biomarker research.
- Pharmaceutical Analysis: Comprehensive examination of drug compounds and contaminants.
Thermal Analysis, Rheometry, and Calorimetry
Instruments from the TA segment are pivotal in the characterization of materials across their thermal and physical properties. They contribute to the development processes in various sectors, including pharmaceuticals, polymers, and food safety.
Specific areas of focus include:
- Material Stability Testing: Evaluating the behavior of materials under thermal stress.
- Rheological Assessment: Understanding the flow properties and interaction behaviors of materials.
The ability to measure and predict material characteristics is crucial for product development in numerous industries.
D. Research and Development
Waters Corporation is dedicated to advancing its technological offerings through active research and development (R&D). With R&D expenditures reaching approximately $175 million in 2023, the company focuses on the continuous enhancement of existing products and the development of new innovations. The majority of R&D activities are centered at the Milford facility, with significant contributions from other sites specialized in mass spectrometry and materials characterization.
The company’s R&D efforts are bolstered by strategic collaborations with academic institutions and research organizations, exemplified by the establishment of a laboratory in Cambridge, Massachusetts, aimed at fostering community-driven scientific advancements.
E. Manufacturing and Distribution
Waters Corporation emphasizes high-quality production standards across its manufacturing facilities located primarily in the United States and Europe. The company’s production facilities maintain various certifications, including ISO 9001:2015 and ISO 13485:2016, ensuring compliance with stringent quality standards.
Key manufacturing sites include:
- Milford, Massachusetts: Assembly of LC instruments.
- Taunton, Massachusetts and Wexford, Ireland: Production of chromatography columns and consumables.
- Wilmslow, England: Manufacturing of mass spectrometry instruments.
The company’s distribution strategy enables global access to its products while ensuring efficient supply chain management. Consistent quality control procedures are pivotal throughout the manufacturing process, which encompasses both in-house and outsourced operations.
F. Global Customers and Sales
Waters Corporation serves a wide array of customers, including multinational pharmaceutical companies, academic and research institutions, governmental agencies, and various industrial sectors. The pharmaceutical market constitutes the company’s largest sector, where ongoing investment in R&D and regulatory compliance drives demand for analytical technologies.
The sales structure comprises a large direct sales and service organization, providing comprehensive support and consultative services tailored to customer needs. With nearly 85 sales offices worldwide, Waters Corporation leverages its specialized workforce to sustain and enhance customer relationships while expanding its installed base of analytical instruments.
G. Competitive Landscape
The analytical instrumentation market is marked by intense competition, characterized by several established players. Key competitors include Agilent Technologies, Thermo Fisher Scientific, and Bruker Corporation, among others. Competitive dynamics hinge on product performance, reliability, and service capabilities, with ongoing technological advancements and diversified product lines influencing market positioning.
The consumables market, particularly chromatography columns, is fragmented, with numerous suppliers competing on parameters such as quality, reproducibility, and performance. Waters Corporation's ability to manufacture its own resins and specialty products is viewed as a significant competitive advantage.
H. Environmental Considerations
Waters Corporation is committed to maintaining compliance with environmental regulations across its operational footprint, emphasizing sustainability in product offerings and operational practices. The company conducts regular assessments to mitigate its environmental impact while advancing its carbon footprint reduction initiatives.
Annual sustainability reports highlight efforts concerning environmental management, demonstrating a proactive approach to climate change adaptation and social responsibility.
Stock Infos
SectorHealth Care
IndustryHealth Services
CEOUdit Batra, Ph. D.
Dividends

Biotechnology
Waters Corporation offers analytical instruments and technologies essential for various applications in biotechnology, including drug characterization, proteomics, and clinical testing, which are crucial for understanding biological processes and developing therapies.

Pharmaceutical Companies
The company's primary market is focused on pharmaceutical development, offering high-performance liquid chromatography (HPLC) and mass spectrometry (MS) systems that are vital for drug discovery and quality control in pharmaceuticals.

Medical Technology
Waters Corporation's analytical technologies, such as mass spectrometry and thermal analysis instruments, play a significant role in medical technology applications, including clinical testing and biomarker research.

Chemical Manufacturing
The company manufactures a range of precision chemistry consumables and analytical systems that are integral to chemical manufacturing processes, including quality assurance and compliance testing.

Intangible Assets
Waters Corp possesses strong patents and proprietary technologies in the field of analytical instruments, which are difficult for competitors to replicate. This intellectual property provides a significant barrier to entry for new entrants and helps maintain a competitive edge.